Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.36 |
| ▸ | HTR3B | O95264 | 5/20 | 0.36 |
| ▸ | HTR3A | P46098 | 5/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277742 | 0.79 | SIRT2 (0.30) | CDK4CCND1 | |
| SCHEMBL30912434 | 0.77 | MAPT (0.45) | CHRNA7KCNH2 | |
| SCHEMBL30912529 | 0.77 | MAPT (0.45) | CHRNA7KCNH2 | |
| SCHEMBL3413859 | 0.77 | MAPT (0.45) | CHRNA7KCNH2 | |
| SCHEMBL13657915 | 0.77 | MAPT (0.45) | CHRNA7KCNH2 | |
| SCHEMBL25900470 | 0.75 | CHRNA7 (0.40) | CHRNA7KCNH2CDK4CCND1 | |
| SCHEMBL4277920 | 0.74 | CHRNA7 (0.34) | CHRNA7KCNH2 | |
| SCHEMBL13657917 | 0.74 | CHRNA7 (0.34) | CHRNA7KCNH2 | |
| SCHEMBL15790567 | 0.70 | CHRNA7 (0.51) | CHRNA7KCNH2 | |
| SCHEMBL3411641 | 0.69 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2265607-B1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2265607-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | Rigel Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009103032-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CHRNA7 4430/4885KCNH2 2389/4885HTR3E 2436/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CHRNA7 4409/4885KCNH2 3103/4885HTR3E 1518/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CHRNA7 4368/4885KCNH2 3162/4885HTR3E 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.